The alarming rise of medicalisation in India

1. At a Glance

• Medicalisation refers to treating non-medical conditions (like body weight/lifestyle patterns) as medical problems requiring drugs or clinical intervention, rather than addressing root behavioural/structural causes [1].
• India's obesity-metabolic disease burden (diabetes, hypertension, fatty liver, dyslipidaemia) is rising sharply, and the policy/market response is trending toward pharmaceutical fixes (e.g., anti-obesity drugs) rather than food-systems reform [1].
• Relevant for GS-II (health policy, governance) and GS-III (science-tech, economy) — tests ability to link corporate/employment practice, drug regulation, and public health policy.
• Illustrates the tension between individual-fitness framing (BMI-based corporate rules) and structural determinants (ultra-processed food proliferation, sedentary urban lifestyles) [1].

2. Why in the News

• Air India announced potential pay cuts/de-rostering for cabin crew with higher Body Mass Index (BMI), framed as a fitness/operational-safety measure [1].
• This coincided with semaglutide (a GLP-1 anti-obesity drug) going off-patent, with nearly 40 products entering the Indian market in the same week — raising concern that medicalisation (drug-based fixes) is being normalised over addressing structural causes of obesity [1].

3. Background & Evolution

• Rising overweight/obesity and metabolic disease prevalence in India has been documented over the past decade, moving from a "lifestyle disease of affluence" to a mass public health concern spanning urban and rural populations [1].
• Parallel global trend: semaglutide was developed and marketed first for type-2 diabetes (as Ozempic) before its anti-obesity indication (as Wegovy) gained traction — its 2026 patent expiry in India opened the market to multiple generic/biosimilar entrants [1].
• Corporate BMI-linked employment policies (as in aviation) mark a new front where medicalised, individual-blame framing enters workplace regulation [1].

4. Core Static Facts

5. Multi-Dimensional Analysis

Social

• Corporate BMI policies risk stigmatising employees rather than addressing systemic causes — raises equity/discrimination concerns in the workplace [1].
• Childhood obesity is rising rapidly, indicating an intergenerational public health crisis, not just an adult lifestyle issue [1].

Economic

• A ~40-product surge in the anti-obesity drug market signals a shift toward a pharmaceutical solution economy, with commercial incentives around patent expiry rather than preventive public health investment [1].
• Employment-linked BMI policy (pay cuts) directly monetises a health metric, shifting cost of "fitness" onto employees rather than systemic food/urban-planning reform [1].

Scientific/Technological

• Semaglutide's off-patent status is expected to sharply lower cost and increase access to anti-obesity pharmacotherapy in India [1].
• Genetic predisposition among Indians/South Asians toward abdominal fat accumulation despite normal BMI ("thin-fat phenotype") complicates BMI-only screening/policy tools [1].

Ethical/Governance

• Core critique: medicalisation (drugs, BMI-based HR rules) is drawing attention away from ultra-processed food proliferation — the more fundamental, upstream driver — reflecting weak regulatory will on food environments [1].
• Raises questions on using a narrow biomarker (BMI) as a proxy for fitness/competence in employment contexts.

Administrative

• No single ministry/regulator was cited in the article as governing HFSS/ultra-processed food labelling or drug-market entry timing — signals a regulatory gap in coordinated obesity policy (food regulation vs. drug approval vs. labour policy) [1].

6. Recent Developments (last 12-18 months)

• April 2026: Air India's BMI-linked crew fitness policy announced, triggering public debate [1].
• April 2026 (same week): Semaglutide's patent expiry in India, with ~40 new anti-obesity products launched [1].

7. Prelims Hooks

• Medicalisation = framing non-medical/lifestyle issues as conditions needing clinical/drug treatment [1].
• Semaglutide is a GLP-1 receptor agonist, originally for type-2 diabetes, later approved for weight management [1].
• Semaglutide went off-patent in India in the week of the reported Air India controversy (April 2026) [1].
• Nearly 40 semaglutide-based products entered the Indian market post-patent expiry [1].
• Air India's controversial move: pay cuts/de-rostering for cabin crew based on BMI [1].
• Roughly 1 in 4 Indians are overweight/obese per the article's cited figures [1].
• Roughly 1 in 10 Indian adults have diabetes; 1 in 3 have hypertension (as cited in the article) [1].
• South Asians/Indians show a genetic predisposition to excess body fat despite lean appearance — sometimes termed the "thin-fat" phenotype [1].
• HFSS = High Fat, Salt, and Sugar content foods — a recurring regulatory/nutrition-labelling term [1].
• Ultra-processed food proliferation is cited as a key, under-addressed driver of the obesity epidemic, contrasted with drug-based solutions [1].
• BMI (Body Mass Index) is the metric used in the Air India policy — a screening tool, not a diagnostic one, criticised for limited applicability to Indian body composition [1].

8. Mains Relevance

• GS-II: Health — issues relating to development and management of social sector/services (health); governance issues in food regulation and labour policy.
• GS-III: Science and Technology — developments in biotechnology/pharmaceuticals; Economy — employment and labour welfare.
• Possible question stems: 1. "Discuss the concept of 'medicalisation' in the context of India's rising obesity burden. Does reliance on pharmacological solutions risk neglecting structural determinants of health?" (GS-II) 2. "Critically examine the adequacy of India's regulatory framework for ultra-processed foods in addressing the obesity and non-communicable disease burden." (GS-II/III) 3. "BMI-linked employment policies raise ethical and equity concerns. Discuss with reference to recent corporate practices in India." (GS-IV/GS-II)

9. Related Topics to Study Next

• NCD (Non-Communicable Disease) burden in India — obesity is one strand of the broader NCD policy challenge.
• FSSAI and food labelling regulations (HFSS norms) — the regulatory gap the article highlights.
• National Nutrition Mission / POSHAN Abhiyaan — India's preventive nutrition policy architecture.
• Right to Health / workplace discrimination law — legal angle on BMI-based employment decisions.
• Pharma patent regime (TRIPS, Indian Patents Act, 1970) — relevant to semaglutide's patent expiry and generic entry.
• Urbanisation and lifestyle disease linkage — sedentary lifestyle, urban planning, and public health.
• Global obesity trends (WHO reports) — comparative international context for benchmarking India's burden.

10. Common Errors / Trap Areas

• Do not confuse semaglutide (GLP-1 receptor agonist, originally anti-diabetic) with insulin or other unrelated diabetes drugs.
• Do not assume a specific ministry (e.g., MoHFW or FSSAI) issued the Air India BMI policy — it is a corporate/airline HR decision, not a government regulation.
• Avoid citing exact NFHS/ICMR-INDIAB percentage figures with false precision — the article uses approximate phrasing ("nearly a quarter," "one in 10," "one in three"); precise official figures were not retrievable from whitelisted sources in this session and should be verified separately before use in answers.
• Don't treat "medicalisation" as synonymous with "healthcare access improvement" — it specifically denotes an over-reliance on clinical/drug labels for social or lifestyle issues, often used critically.
• Avoid assuming semaglutide's patent expiry is India-specific policy — it is a global pharmaceutical patent-cycle event with Indian market implications.